On September 22, 2026, Thailand’s cabinet approved a bill restricting cannabis and cannabis extracts strictly to medical treatment and research purposes. The Health Ministry is responsible for the proposal. The bill is not yet law; it now advances to the House of Representatives. The legislation directly affects approximately 11,000 retail outlets that emerged following cannabis decriminalization in 2022.
📑 Inhaltsverzeichnis
This represents the third attempt to establish a regulatory framework for cannabis since the 2022 liberalization. Previous legislative efforts stalled in parliament. For German-speaking countries, the development is of interest for two reasons: as a case study of liberalization without an accompanying legal framework, and as a signal for a supply chain that also touches German pharmacies.
What the Bill Actually Proposes
The bill’s core provision creates a strict purpose limitation. Cannabis and derived extracts may only be used for medical treatment under professional supervision and for research. Cultivation, manufacturing, import, export, and sales require three-year licenses. Exempt from licensing requirements are roots, stems, branches, leaves, and seeds—plant parts with minimal cannabinoid content.
The proposal also includes protective measures familiar from European debates. Sales to those under 20, pregnant individuals, and nursing mothers would be prohibited. Advertising restrictions would apply to flowers, resin, and consumption devices. Unlicensed production or sales face criminal penalties and fines; prohibited consumption carries monetary sanctions. Health Minister Pattana Promphat summarizes the approach in one statement: cannabis is exclusively for medical purposes, not recreational use.
From 11,000 Retailers to an Estimated 2,000 Medical Facilities
The ministry itself provides the figure illustrating the scale of this transition. Of approximately 11,000 existing retail outlets, the government estimates roughly 2,000 will be capable of meeting medical facility requirements by 2028. This includes employing qualified staff and dispensing only on medical prescription. Existing licenses will expire on a staggered schedule through 2028.
This continues a development we’ve tracked for years. In 2025, we reported on Thailand’s reversal and the prohibition of recreational consumption. A year later, our assessment showed 7,000 closed shops and a market restructuring itself. Our retrospective illustrated how permissive early enforcement was, documenting that police were directed to be lenient with cannabis cultivators.
Why a Third Legislative Attempt Became Necessary
Thailand became Asia’s first country to remove cannabis from its narcotics list in 2022. However, no control law governing the plant’s handling ever followed. This regulatory void enabled retail commerce that was formally justified as medical yet functionally served a recreational market. The government attempted to reverse this situation through ordinances and decrees without legislative backing.
This sequence extends beyond Thailand’s borders. A liberalization without supporting legal architecture creates structures that become extremely difficult to recapture later. Those following Germany’s ongoing debate about evaluating its cannabis consumption law will find arguments both sides can claim. Some see proof that clear regulation is essential from the outset. Others observe how challenging it is to reverse a legal market once established.
Implications for German Import Markets
Germany is Europe’s largest medicinal cannabis market and meets nearly all its demand through imports. Our article on 300 tons of imports and calls for stricter regulations illustrates the scale. Thailand is not a primary supplier, but several European companies have built supply chains there in recent years.
For these projects, the news cuts both ways. The restriction to medical and research purposes aligns fundamentally with exporting to Europe, as it drives production toward pharmaceutical standards. Simultaneously, import and export now explicitly require licenses valid for only three years. This offers little long-term planning security. Similar course corrections are occurring elsewhere, including with Portuguese export certificates and Australia’s regulatory action against closed-loop prescriptions.
Frequently Asked Questions
Is cannabis now illegal in Thailand again?
Not yet. The cabinet has only approved a draft that must go through parliamentary procedures. Until passage, the current legal status applies, including the stricter regulations implemented since 2025.
What happens to existing cannabis shops?
Their licenses expire on a staggered schedule through 2028. Those wanting to continue must meet requirements for medical facilities: employ qualified staff and dispense only on prescription. The ministry estimates approximately 2,000 facilities will remain.
Can tourists still buy cannabis?
The bill links dispensing to medical indication and physician prescription. Recreational purchases would be excluded. Current regulations have required prescriptions since 2025, though enforcement has been inconsistent.
Does this affect medicinal cannabis in German pharmacies?
Not in the short term. Thailand is not a primary supplier to the German market, which draws mainly from Canada, Portugal, Denmark, and Australia. Medium-term, new export licensing could increase costs or delays for individual supply chains.
Which plant parts remain exempt from licensing?
The bill exempts roots, stems, branches, leaves, and seeds. These contain minimal cannabinoids and have traditional use in Thai cuisine and folk medicine. Flowers and resin remain fully subject to licensing.
Sollte Cannabis in Deutschland nur für die Medizin erlaubt sein?
Sources: Cabinet Resolution September 22, 2026; Bangkok Post, Thai PBS World, Business of Cannabis, and Hanfjournal, September 23, 2026.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
